<DOC>
	<DOCNO>NCT01018823</DOCNO>
	<brief_summary>Ertugliflozin ( PF-04971729 , MK-8835 ) development treatment Type 2 Diabetes . The primary purpose trial evaluate safety tolerability , pharmacokinetics pharmacodynamics , multiple oral dos ertugliflozin .</brief_summary>
	<brief_title>A Multiple Dose Study Of Ertugliflozin ( PF-04971729 , MK-8835 ) In Otherwise Healthy Overweight And Obese Volunteers ( MK-8835-037 )</brief_title>
	<detailed_description>To evaluate safety tolerability , pharmacokinetics ( PK ) , pharmacodynamics , multiple oral dos ertugliflozin .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 26.5 35.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Evidence glycosuria , define positive urine dipstick test ; Fasting ( least 10 hour ) serum triglyceride &gt; 300 mg/dL ; Fasting ( least 10 hour ) LDLcholesterol &gt; 190 mg/dL ; Fasting ( least 10 hour ) serum 25OH Vitamin D concentration &lt; 20 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>